The Science Behind Xeomin
XEOMIN® (incobotulinumtoxinA) Mechanism of Action
XEOMIN® (incobotulinumtoxinA) blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. Impulse transmission is re-established by the formation of new nerve endings.
In nature, Clostridium botulinum produces the toxin in association with accessory proteins. Manufacturers utilize this naturally occurring protein complex to produce therapeutic botulinum toxin products. Now Merz introduces XEOMIN® (incobotulinumtoxinA) which employs a proprietary manufacturing process that isolates the therapeutic component and eliminates these accessory proteins. XEOMIN® (incobotulinumtoxinA) has been formulated to have high biologic activity with a low protein load.
State-of-the-art manufacturing process
- XEOMIN is a purified botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
- XEOMIN science isolates the active toxin from the non-toxic accessory proteins